Nutra Pharma is announcing today the first of several growth steps that will expand the Company’s core business strengths as well as its reach into important commercial markets.
February 16, 2016 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today a key expansion of personnel with the addition of Thomas W. Northrop as the Company's Senior Commercial Development Officer.
Thomas W. Northrop, MHA, FACHE holds a Masters in Health Management from Duke University’s Fuqua School of Business, and is a Fellow of the American College of Healthcare Executives. Mr. Northrop has led hospitals, healthcare networks, and physician groups in several regions of the country, and has worked extensively in developing new healthcare businesses. He is a member of Tri-State Capital Partners, LLC (TSCP), a New York-based management advisory & investment firm, which brings combined management resources, strategy development & implementation, and capital funding expertise to promising businesses.
"The addition of Tom Northrop and TriState’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the Company’s growth strategy for 2016," commented Rik J Deitsch, CEO of Nutra Pharma. “TriState believes, as we do, that Nutra Pharma has a powerful set of products that effectively combat chronic – often debilitating – pain, without the damaging side effects common to other treatments. We have been working closely over the last few months and they are now committed to helping us achieve our growth goals," he continued. "With Tri-State’s support, we now have the tools and a depth of resources that will allow for expansion into multiple markets, as well as to help accelerate the development and deployment of our prescription drug candidates," he concluded.
Northrop will lead new marketing efforts in healthcare, governmental and military entities, aging athletes and the elderly, as well as the completion of scientifically rigorous pain relief trials in multiple settings.
“Chronic pain is a major common factor in the lives of millions of Americans – Civilians, Active-Duty Military, and Veterans alike,” commented Tom Northrop. “Nutra Pharma’s pain relief solutions are non-opiate, non-narcotic, and non-addictive; they’re safe for the kidneys, liver, and stomach; and they don’t adversely affect cognitive skills or motor function; all while providing, powerful, long-lasting relief," he continued. "With opioid abuse at record levels, and increased recognition of the dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID) like ibuprofen, Nutra Pharma is well positioned to help an enormous global market, and to reap the associated rewards,” he concluded.
Additional steps in Nutra Pharma’s growth plans will be announced shortly.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The management addition of Tom Northrop and TriState Capital Partners should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.